The Trump MFN EO: Terrible as a Policy Prescription … but Solid as a PR Stunt

So there won’t be news this week on the government’s opening offer** around price controls for the first 10 medicines selected under the Inflation Reduction Act. Companies will get the

If you’re at the Tufts CEVR meeting tomorrow, please track me down! If you want to search Cost Curve back issues or link to anything you read here, the web

I had really hoped that nothing was going to happen over the latter half of last week so that we could all ease into the end-of-year sprint. But it turns